Stock LWACU LOCT WALK
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Other languages LOCT WALK Nasdaq

Equities

LWACU

US54015L3015

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sector Update: Health Care Stocks Rise in Late Afternoon Trading
Top Midday Decliners
Sector Update: Health Care Stocks Advance Monday Afternoon
EFFECTOR Therapeutics to Shut Down Operations, Seeking Strategic Alternatives
EFFECTOR Therapeutics, Inc Appoints Craig R. Jalbert as CEO
EFFECTOR Therapeutics, Inc. Appoints Craig R. Jalbert as President, Treasurer and Secretary, and Sole Member of the Board
EFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Top Midday Decliners
EFFECTOR Therapeutics, Inc. Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
Top Premarket Decliners
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
EFFECTOR Therapeutics Says Study of Zotatifin in Breast Cancer Patients Yields 'Positive' Interim Data
EFFECTOR Therapeutics, Inc. Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Er+ Metastatic Breast Cancer Patients
EFFECTOR Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of Er+/Her2- Advanced Metastatic Breast Cancer
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Effector Therapeutics, Inc. Announces Initiation of Dosing in an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Relapsed/Refractory Acute Myeloid Leukemia
EFFECTOR Therapeutics, Inc. Appoints Caroline Loewy to its Board of Directors
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
EFFECTOR Therapeutics Closes $16.2 Million Registered Direct Offering, Private Placement
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EFTR Stock
  4. LWACU Stock
  5. News LOCT WALK
  6. Other languages